Should I stay on 5mg Mounjaro, or is it time to move up?

You've been on 5mg for a few weeks and you're not sure whether to push on

This is a question our prescribers hear most weeks, in some form. You started at 2.5mg, your body adjusted reasonably well, the dose stepped up to 5mg, and now you are somewhere between "this is working" and "I'm not sure this is working fast enough." Both feelings are entirely normal, and neither one automatically tells you what to do next.

Mounjaro's titration schedule exists primarily to manage tolerability, not to rush you to the highest dose as quickly as possible. The 2.5mg pen is designed to let your gut adapt to the medicine; 5mg is where clinical weight loss generally starts to take hold for most people. The NHS medicines page for tirzepatide describes the standard escalation pattern: doses increase in roughly four-week steps, but the timing is always subject to individual tolerance. Staying at 5mg for longer than four weeks is not unusual. It is, in fact, sometimes the most sensible thing to do.

If you landed at 5mg and immediately felt significantly nauseous, fatigued or unsettled, your prescriber may well recommend you give it more time before stepping up. Discomfort that fades after the first week or two is typical. Discomfort that is still disrupting meals and daily life at week four is a signal worth raising, and one of the strongest reasons to stay where you are. More on side effects below.

For context on the 2.5mg phase that came before this one, and what it was designed to do, this page covers the 2.5mg decision in detail.

What "staying on 5mg" means in terms of results, and when to expect them

Clinical trial data from the SURMOUNT programme, involving thousands of adults with obesity, showed that tirzepatide produces progressively greater weight reduction as the dose increases, with the largest average losses seen at 10mg and 15mg. That is a fact. It is not, however, a reason to hurry through lower doses if your body has not settled.

Weight loss at 5mg can be meaningful, particularly in the first few months of treatment when the body is still adapting to reduced appetite and slower gastric emptying. The question is not simply "am I losing weight" but "am I losing at a rate that is sustainable and that my body can manage well." A rapid loss accompanied by persistent nausea, vomiting or fatigue may be less useful clinically than a steadier loss with good tolerance.

NICE's appraisal of tirzepatide, published as TA1026, frames the treatment goal as sustained weight management alongside lifestyle change, not the fastest possible descent through the dose schedule. If, after six months at the highest tolerated dose, you have lost less than five percent of your body weight, the guidance recommends reviewing whether to continue. That review threshold is about the highest tolerated dose, not any specific number on the pen.

People who are still seeing steady loss at 5mg, tolerating it well, and feel in control of their appetite often have good clinical reasons to stay there. Whether that applies to you is something a prescriber can assess properly, and if you want a fuller picture of the thinking behind that decision, our page on how long to stay on 5mg Mounjaro goes into the detail that a general article cannot.

Side effects at 5mg: when they mean stay, and when they mean something else

The most common side effects at this dose are gastrointestinal: nausea, loose stools, constipation, reflux and burping. They tend to be most noticeable in the first one to two weeks after starting or after a dose step, and they frequently settle without any intervention beyond eating smaller portions, avoiding fatty foods and staying well hydrated.

Staying at 5mg is clinically reasonable if side effects are present but manageable and gradually improving. Staying at 5mg is also reasonable if you stepped up from 2.5mg and the jump felt significant, your prescriber may want to let the new dose bed in for longer before any further increase. Some people stay at one dose for eight, ten or even twelve weeks rather than the minimum four, and this is within the framework the SmPC and UK prescribers work within.

What warrants medical attention rather than simply staying put: severe, persistent stomach pain that spreads to your back should be assessed urgently, as acute pancreatitis is a recognised but infrequent side effect of GLP-1 medicines. The MHRA's Yellow Card scheme allows patients to report any suspected side effects directly, which is worth knowing at any dose. Severe vomiting leading to dehydration, or an allergic reaction, are also reasons to seek help promptly rather than waiting for a scheduled review.

For a more focused look at where 5mg fits in the dose progression, and how prescribers tend to think about the step from 5mg to 7.5mg, this page on moving to 5mg and this one on dose increases generally cover the adjacent decisions well.

How a prescriber actually makes this call

The decision to stay at 5mg or move up is not made by looking at one number. A prescriber will typically consider your rate of weight loss since starting or since your last dose change, whether side effects have been tolerable, any changes in your health background, and whether your lifestyle context (eating patterns, activity, stress) has shifted.

At nume, every repeat order goes through a fresh clinical review. A real clinician reads your answers; no automated system makes dose decisions. This is especially relevant at the 5mg mark, because it is genuinely the dose where people diverge: some are ready to move on, some are not, and a few find it the dose they stay on for months with good results.

The Mounjaro overview page covers the full licensed dose range and how the treatment works at each level. If cost is a factor in your thinking about whether to stay on treatment, our breakdown of Mounjaro pricing in the UK is worth reading, it explains what legitimate private treatment includes and why the price varies between providers. The short answer is that prescription-only medicines should never be chosen on price alone, and any route that skips clinical review is not a route worth taking.

If you would like a prescriber to look at your specific situation and help you decide, checking your eligibility with us takes a few minutes and costs nothing.